Colorectal Cancer Clinical Trial
— DASHOfficial title:
Technology to Reduce Sedentary Behavior Before and After Cancer Surgery
Verified date | May 2021 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this research is to develop and test a technology-supported intervention to reduce sedentary behavior before and after cancer surgery. Surgical oncology patients are at elevated risk for postoperative complications and readmissions. Sedentary behavior increases markedly after surgery and hospitalization, and reducing sedentary behavior around the time of cancer surgery could reduce risk while also empowering cancer patients to take a more active role in their recovery.
Status | Completed |
Enrollment | 26 |
Est. completion date | May 14, 2021 |
Est. primary completion date | May 14, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Scheduled for curative surgical treatment of metastatic colorectal or peritoneal cancer at UPMC Shadyside - Ability to stand and walk unassisted prior to surgery - Identified at least two weeks prior to their scheduled surgery date Exclusion Criteria: - Unable to read and write in English |
Country | Name | City | State |
---|---|---|---|
United States | UPMC Shadyside | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pittsburgh | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retention | Percentage of those enrolled who completed the program | 30 days post-discharge | |
Primary | Acceptability | Post-intervention interviews will be conducted to assess acceptability of the program | 30-days post-discharge | |
Primary | Adherence | Percentages of assessments completed and prompts after which steps were detected | 30-days post-discharge | |
Secondary | Total objective sedentary behavior | A Bluetooth enabled activity monitor worn throughout the study will estimate the total amount of time spent in sedentary behavior per day | Change from baseline to 30 days post-discharge | |
Secondary | Objective physical activity | A Bluetooth enabled activity monitor worn throughout the study will estimate of number of steps/day. | Change from baseline to 30 days post-discharge | |
Secondary | Patient-reported symptoms | Depressive (CES-D) and physical symptom severity (adapted from the MD Anderson Symptom Inventory) | Change from baseline to 30 days post-discharge | |
Secondary | Patient-reported quality of life | Quality of life (FACT) | Change from baseline to 30 days post-discharge | |
Secondary | Inflammatory biomarkers | Plasma levels of IL-6 and CRP | 2 weeks post-discharge | |
Secondary | Morbidity | Grade 3-4 surgical complications within 30 days after index hospital discharge will be extracted from medical records | 30 days post-discharge | |
Secondary | Mean sedentary behavior bout | A Bluetooth enabled activity monitor will be used to estimate mean daily sedentary bout | Change from baseline to 30 days post-discharge | |
Secondary | Maximum sedentary behavior bout | A Bluetooth enabled activity monitor will be used to estimate maximum daily sedentary bout | Change from baseline to 30 days post-discharge | |
Secondary | Readmission | Readmissions within 30 days after index hospital discharge will be extracted from medical records | 30 days post-discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |